BioCryst Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BioCryst Pharma (BCRX) Posts Surprise Q2 Profit
August 7, 2015 6:52 AM EDTBioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.07, $0.29 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $7.1 million.
Cash, cash equivalents and investments increased to $132.0 million at June 30, 2015, compared to $114.0 million at December 31, 2014. This increase resulted primarily from the RAPIVAB upfront licensing... More
